An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients

This study has been withdrawn prior to enrollment.
(Program Cancelled.)
Sponsor:
Information provided by (Responsible Party):
Alza Corporation, DE, USA
ClinicalTrials.gov Identifier:
NCT00666393
First received: April 22, 2008
Last updated: February 28, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to evaluate the safety and clinical utility of fentanyl HCl 40 mcg system for the management of postoperative pain in pediatric inpatients.


Condition Intervention Phase
Pain, Postoperative
Pediatrics
Drug: fentanyl iontophoretic transdermal system (40mcg) No placebo
Drug: fentanyl iontophoretic transdermal system (40mcg)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Evaluation of Safety of the IONSYS System [Fentanyl Iontophoretic Transdermal System (40ug) for Management of Acute Post-Operative Pain in Pediatric Patients

Resource links provided by NLM:


Further study details as provided by Alza Corporation, DE, USA:

Primary Outcome Measures:
  • Any adverse events will be recorded. Oxygen saturation will be monitored continuously. Vital signs (BP, HR, RR, T), oxygen saturation, and concomitant medications will be recorded at Hours 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and every 4 hours thereafter. [ Time Frame: Safety outcomes will be collected at intervals throughout the drug system application for a maximum of 72 hours. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Patient Global Assessment, Investigator Global Assessment and Parent Assessment of Patient Use will be completed every 24 hours. Serum fentanyl concentration will be collected at Hours 3, 6,12, and 24. [ Time Frame: Patient, Investigator and Parent Assessments of the treatment will be completed every 24 hours for a maximum of 72 hours. Pharmacokinetic measurements will be completed 4 times during every 24 hours of treatment for a maximum of 12 times over 72 hours. ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: October 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001 Drug: fentanyl iontophoretic transdermal system (40mcg) No placebo
40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
Drug: fentanyl iontophoretic transdermal system (40mcg)
40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours

Detailed Description:

This will be a multicenter, open-label study in which hospitalized pediatric post-operative patients will receive the fentanyl HCl 40 mcg system for up to 3 consecutive days. After their surgery, patients will be brought to the recovery room for initial observation following general or regional anesthesia for abdominal, pelvic/genitourinary, orthopedic, or thoracic surgery. Post surgery procedures will be preformed and when analgesia is required, the patient will be titrated to analgesic comfort (a pain score < 4 on a scale 0-10) for at least 30 minutes with an intravenous opioid as clinically appropriate. After a patient has been comfortable (pain intensity of < 4 on 0 -10 color visual analog scale ) for > 30 minutes and has been monitored during recovery and is awake, able to answer questions and follow commands he/she will be assessed for pain intensity, vital signs, and oxygen saturation (amount of oxygen in the blood). If the patient meets study entry criteria, baseline assessments (pain intensity, vital signs, and oxygen saturation) will be completed and the fentanyl HCl 40 mcg system will be applied. During the first 3-hours of the treatment, if a patient successfully completed an on-demand dose and pain relief was still inadequate, the patient could deliver another dose of fentanyl, or be re-titrated to comfort with single or multiple intravenous doses of supplemental opioid medication (IV fentanyl or IV morphine) per study physician's clinical discretion. Supplemental IV doses of opioid medications can be administered in the first 3-hours of system application, but are prohibited after Hour 3. If pain control is judged inadequate with the combined use of fentanyl HCl 40 mcg system and the use of supplemental analgesia, the patient may be withdrawn from the study. Patients will receive fentanyl HCl 40 mcg system. Fentanyl will be delivered upon patient activation over 10 minutes for a maximum of 6 doses/hour for up to 24 hrs or 80 total doses whichever occurs first for up to three consecutive days.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patients must: weigh >= 40 kg
  • be scheduled for abdominal, pelvic/genitourinary, orthopedic, or thoracic surgery
  • Be expected by the investigator's staff to require injected opioid analgesia for at least 24 hours after surgery
  • Be judged by the investigator's staff to be capable of understanding and cooperating with the requirements of the study.

Exclusion Criteria:

  • Patients who have undergone any surgery on the airway, head or neck
  • Patients who are expected to require intensive care
  • Patients who require airway(breathing) support after their surgery
  • Patients who received intra-operative (during surgery) and/or post-operative (after surgery) administration of opioids other than morphine, hydromorphone, fentanyl, sufentanil or alfentanil
  • Patients with active generalized skin disorders or active local skin disease that precludes the application of fentanyl iontophoretic transdermal system(40 mcg).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00666393

Sponsors and Collaborators
Alza Corporation, DE, USA
Investigators
Study Director: Alza Corporation Clinical Trial ALZA
  More Information

No publications provided

Responsible Party: Alza Corporation, DE, USA
ClinicalTrials.gov Identifier: NCT00666393     History of Changes
Other Study ID Numbers: CR013048, C-2006-007
Study First Received: April 22, 2008
Last Updated: February 28, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Alza Corporation, DE, USA:
IONSYS™
Pain, Postoperative
Analgesia, Patient-Controlled
Opioids
Pediatrics

Additional relevant MeSH terms:
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Signs and Symptoms
Fentanyl
Adjuvants, Anesthesia
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Analgesics, Opioid

ClinicalTrials.gov processed this record on April 22, 2014